# Axon Enterprise, Inc.: financial statements, quarterly

AXON · Nasdaq · CIK 1069183 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/axon.md) · [Financials](/companies/axon/financials.md) · [Filings](/companies/axon/filings.md) · [Insiders](/companies/axon/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/axon/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [413](/filings/0001069183-25-000075.md) | [430](/filings/0001069183-25-000075.md) | [460](/filings/0001069183-25-000077.md) | [503](/filings/0001069183-25-000181.md) | [544](/filings/0001628280-25-049143.md) | [575 d](/filings/0001628280-26-011360.md) | [604](/filings/0001628280-26-031542.md) | [669](/filings/0001628280-26-053646.md) | [711](/filings/0001628280-25-049143.md) | [797 d](/filings/0001628280-26-011360.md) | [807](/filings/0001628280-26-031542.md) | [904](/filings/0001628280-26-053646.md) |
| Cost of revenue | $m | [157](/filings/0001069183-25-000075.md) | [166](/filings/0001069183-25-000075.md) | [201](/filings/0001069183-25-000077.md) | [197](/filings/0001069183-25-000181.md) | [214](/filings/0001628280-25-049143.md) | [229 d](/filings/0001628280-26-011360.md) | [238](/filings/0001628280-26-031542.md) | [265](/filings/0001628280-26-053646.md) | [283](/filings/0001628280-25-049143.md) | [335 d](/filings/0001628280-26-011360.md) | [330](/filings/0001628280-26-031542.md) | [358](/filings/0001628280-26-053646.md) |
| Gross profit | $m | [257](/filings/0001069183-25-000075.md) | [264](/filings/0001069183-25-000075.md) | [259](/filings/0001069183-25-000077.md) | [306](/filings/0001069183-25-000181.md) | [331](/filings/0001628280-25-049143.md) | [346 d](/filings/0001628280-26-011360.md) | [366](/filings/0001628280-26-031542.md) | [404](/filings/0001628280-26-053646.md) | [427](/filings/0001628280-25-049143.md) | [461 d](/filings/0001628280-26-011360.md) | [477](/filings/0001628280-26-031542.md) | [546](/filings/0001628280-26-053646.md) |
| Research and development | $m | [76.9](/filings/0001069183-24-000061.md) | [84.0 d](/filings/0001628280-26-011360.md) | [91.1](/filings/0001069183-25-000077.md) | [101](/filings/0001069183-25-000181.md) | [114](/filings/0001628280-25-049143.md) | [135 d](/filings/0001628280-26-011360.md) | [151](/filings/0001628280-26-031542.md) | [163](/filings/0001628280-26-053646.md) | [177](/filings/0001628280-25-049143.md) | [194 d](/filings/0001628280-26-011360.md) | [189](/filings/0001628280-26-031542.md) | [209](/filings/0001628280-26-053646.md) |
| Selling, general and administrative | $m | [122](/filings/0001069183-25-000075.md) | [137](/filings/0001069183-25-000075.md) | [151](/filings/0001069183-25-000077.md) | [171](/filings/0001069183-25-000181.md) | [192](/filings/0001628280-25-049143.md) | [227 d](/filings/0001628280-26-011360.md) | [224](/filings/0001628280-26-031542.md) | [242](/filings/0001628280-26-053646.md) | [253](/filings/0001628280-25-049143.md) | [317 d](/filings/0001628280-26-011360.md) | [259](/filings/0001628280-26-031542.md) | [291](/filings/0001628280-26-053646.md) |
| Operating income | $m | [57.4](/filings/0001069183-25-000075.md) | [42.7](/filings/0001069183-25-000075.md) | [16.5](/filings/0001069183-25-000077.md) | [33.8](/filings/0001069183-25-000181.md) | [24.1](/filings/0001628280-25-049143.md) | [(15.8) d](/filings/0001628280-26-011360.md) | [(8.8)](/filings/0001628280-26-031542.md) | [(1.0)](/filings/0001628280-26-053646.md) | [(2.1)](/filings/0001628280-25-049143.md) | [(50.1) d](/filings/0001628280-26-011360.md) | [29.2](/filings/0001628280-26-031542.md) | [46.8](/filings/0001628280-26-053646.md) |
| Interest expense | $m | not reported | not reported | [1.8](/filings/0001069183-25-000077.md) | [1.9](/filings/0001069183-25-000181.md) | [1.6](/filings/0001628280-25-049143.md) | [1.8 d](/filings/0001628280-26-011360.md) | [7.8](/filings/0001628280-26-031542.md) | [28.7](/filings/0001628280-26-053646.md) | [28.9](/filings/0001628280-25-049143.md) | [28.8 d](/filings/0001628280-26-011360.md) | [28.6](/filings/0001628280-26-031542.md) | [28.1](/filings/0001628280-26-053646.md) |
| Income tax | $m | [10.4](/filings/0001069183-25-000075.md) | [(1.3)](/filings/0001069183-25-000075.md) | [32.5](/filings/0001069183-25-000077.md) | [10.0](/filings/0001069183-25-000181.md) | [12.5](/filings/0001628280-25-049143.md) | [(50.6) d](/filings/0001628280-26-011360.md) | [20.4](/filings/0001628280-26-031542.md) | [(75.0)](/filings/0001628280-26-053646.md) | [17.9](/filings/0001628280-25-049143.md) | [(69.0) d](/filings/0001628280-26-011360.md) | [30.9](/filings/0001628280-26-031542.md) | [3.3](/filings/0001628280-26-053646.md) |
| Net income | $m | [61.3](/filings/0001069183-25-000075.md) | [57.1](/filings/0001069183-25-000075.md) | [133](/filings/0001628280-25-049143.md) | [41.5](/filings/0001628280-25-049143.md) | [67.0](/filings/0001628280-25-049143.md) | [135 d](/filings/0001628280-26-011360.md) | [88.0](/filings/0001628280-26-053646.md) | [36.1](/filings/0001628280-26-053646.md) | [(2.2)](/filings/0001628280-25-049143.md) | [2.7 d](/filings/0001628280-26-011360.md) | [169](/filings/0001628280-26-053646.md) | [29.4](/filings/0001628280-26-053646.md) |
| Diluted EPS | $ per share | [0.81](/filings/0001069183-25-000075.md) | [0.75](/filings/0001069183-25-000075.md) | [1.73](/filings/0001069183-25-000077.md) | [0.53](/filings/0001069183-25-000181.md) | [0.86](/filings/0001628280-25-049143.md) | not reported | [1.08](/filings/0001628280-26-031542.md) | [0.44](/filings/0001628280-26-053646.md) | [(0.03)](/filings/0001628280-25-049143.md) | not reported | [2.05](/filings/0001628280-26-031542.md) | [0.36](/filings/0001628280-26-053646.md) |
| Basic EPS | $ per share | [0.82](/filings/0001069183-25-000075.md) | [0.76](/filings/0001069183-25-000075.md) | [1.77](/filings/0001069183-25-000077.md) | [0.55](/filings/0001069183-25-000181.md) | [0.89](/filings/0001628280-25-049143.md) | not reported | [1.14](/filings/0001628280-26-031542.md) | [0.46](/filings/0001628280-26-053646.md) | [(0.03)](/filings/0001628280-25-049143.md) | not reported | [2.11](/filings/0001628280-26-031542.md) | [0.37](/filings/0001628280-26-053646.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [406](/filings/0001069183-24-000061.md) | [599](/filings/0001628280-26-011360.md) | [404](/filings/0001069183-25-000077.md) | [566](/filings/0001069183-25-000181.md) | [695](/filings/0001628280-25-049143.md) | [455](/filings/0001628280-26-011360.md) | [1,093](/filings/0001628280-26-031542.md) | [615](/filings/0001628280-26-053646.md) | [1,424](/filings/0001628280-25-049143.md) | [1,201](/filings/0001628280-26-053646.md) | [459](/filings/0001628280-26-031542.md) | [598](/filings/0001628280-26-053646.md) |
| Current assets | $m | [2,258](/filings/0001558370-23-018023.md) | [2,394](/filings/0001069183-25-000075.md) | [2,200](/filings/0001069183-25-000075.md) | [2,206](/filings/0001069183-24-000049.md) | [2,434](/filings/0001069183-25-000075.md) | [2,297](/filings/0001628280-26-011360.md) | [3,777](/filings/0001069183-25-000077.md) | [3,828](/filings/0001069183-25-000181.md) | [4,217](/filings/0001628280-25-049143.md) | [3,713](/filings/0001628280-26-053646.md) | [2,744](/filings/0001628280-26-031542.md) | [3,005](/filings/0001628280-26-053646.md) |
| Total assets | $m | [3,254](/filings/0001558370-23-018023.md) | [3,409](/filings/0001069183-25-000075.md) | [3,585](/filings/0001069183-25-000075.md) | [3,742](/filings/0001069183-24-000049.md) | [4,006](/filings/0001069183-25-000075.md) | [4,475](/filings/0001628280-26-011360.md) | [6,083](/filings/0001069183-25-000077.md) | [6,215](/filings/0001069183-25-000181.md) | [6,657](/filings/0001628280-25-049143.md) | [7,000](/filings/0001628280-26-053646.md) | [7,067](/filings/0001628280-26-031542.md) | [7,481](/filings/0001628280-26-053646.md) |
| Current liabilities | $m | [718](/filings/0001558370-23-018023.md) | [762](/filings/0001069183-25-000075.md) | [1,397](/filings/0001069183-25-000075.md) | [766](/filings/0001069183-24-000049.md) | [1,503](/filings/0001069183-25-000075.md) | [1,678](/filings/0001628280-26-011360.md) | [1,337](/filings/0001069183-25-000077.md) | [1,297](/filings/0001069183-25-000181.md) | [1,350](/filings/0001628280-25-049143.md) | [1,470](/filings/0001628280-26-053646.md) | [1,208](/filings/0001628280-26-031542.md) | [1,398](/filings/0001628280-26-053646.md) |
| Total liabilities | $m | [1,733](/filings/0001558370-23-018023.md) | [1,793](/filings/0001069183-25-000075.md) | [1,764](/filings/0001069183-25-000075.md) | [1,814](/filings/0001069183-24-000049.md) | [1,906](/filings/0001069183-25-000075.md) | [2,147](/filings/0001628280-26-011360.md) | [3,527](/filings/0001069183-25-000077.md) | [3,483](/filings/0001069183-25-000181.md) | [3,630](/filings/0001628280-25-049143.md) | [3,758](/filings/0001628280-26-053646.md) | [3,533](/filings/0001628280-26-031542.md) | [3,807](/filings/0001628280-26-053646.md) |
| Long-term debt | $m | not reported | [677](/filings/0001069183-25-000075.md) | not reported | not reported | not reported | [0.0](/filings/0001628280-26-011360.md) | [1,728](/filings/0001069183-25-000077.md) | [1,729](/filings/0001069183-25-000181.md) | [1,729](/filings/0001628280-25-049143.md) | [1,730](/filings/0001628280-26-053646.md) | [1,731](/filings/0001628280-26-031542.md) | [1,732](/filings/0001628280-26-053646.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001069183-25-000075.md) | not reported | not reported | not reported | [680](/filings/0001628280-26-011360.md) | [279](/filings/0001069183-25-000077.md) | [279](/filings/0001069183-25-000181.md) | [280](/filings/0001628280-25-049143.md) | [80.6](/filings/0001628280-26-053646.md) | [0.0](/filings/0001628280-26-031542.md) | [0.0](/filings/0001628280-26-053646.md) |
| Shareholders' equity | $m | [1,525](/filings/0001069183-24-000061.md) | [1,616](/filings/0001628280-26-011360.md) | [1,822](/filings/0001628280-25-049143.md) | [1,933](/filings/0001628280-25-049143.md) | [2,100](/filings/0001628280-25-049143.md) | [2,328](/filings/0001628280-26-053646.md) | [2,556](/filings/0001628280-26-053646.md) | [2,732](/filings/0001628280-26-053646.md) | [3,028](/filings/0001628280-25-049143.md) | [3,243](/filings/0001628280-26-053646.md) | [3,534](/filings/0001628280-26-053646.md) | [3,675](/filings/0001628280-26-053646.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [62.9 d](/filings/0001069183-24-000061.md) | [140 d](/filings/0001628280-26-011360.md) | [(15.9)](/filings/0001069183-25-000077.md) | [82.8 d](/filings/0001069183-25-000181.md) | [91.3 d](/filings/0001628280-25-049143.md) | [250 d](/filings/0001628280-26-011360.md) | [25.8](/filings/0001628280-26-031542.md) | [(91.7) d](/filings/0001628280-26-053646.md) | [60.0 d](/filings/0001628280-25-049143.md) | [217 d](/filings/0001628280-26-011360.md) | [(31.5)](/filings/0001628280-26-031542.md) | [20.1 d](/filings/0001628280-26-053646.md) |
| Capital expenditure | $m | [14.0 d](/filings/0001069183-24-000061.md) | [24.0 d](/filings/0001628280-26-011360.md) | [16.2](/filings/0001069183-25-000077.md) | [11.3 d](/filings/0001069183-25-000181.md) | [26.5 d](/filings/0001628280-25-049143.md) | [24.8 d](/filings/0001628280-26-011360.md) | [24.9](/filings/0001628280-26-031542.md) | [23.0 d](/filings/0001628280-26-053646.md) | [26.6 d](/filings/0001628280-25-049143.md) | [61.8 d](/filings/0001628280-26-011360.md) | [23.1](/filings/0001628280-26-031542.md) | [21.0 d](/filings/0001628280-26-053646.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [72.5](/filings/0001558370-23-018023.md) | [73.9](/filings/0001069183-24-000032.md) | [75.8](/filings/0001069183-24-000049.md) | [76.0](/filings/0001069183-24-000061.md) | [77.1](/filings/0001069183-25-000077.md) | [77.6](/filings/0001069183-25-000181.md) | [78.1](/filings/0001628280-25-049143.md) | [81.5](/filings/0001628280-26-031542.md) | [82.1](/filings/0001628280-26-053646.md) | [78.4](/filings/0001628280-25-049143.md) | [82.5](/filings/0001628280-26-031542.md) | [82.5](/filings/0001628280-26-053646.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 81,237,415 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-053646.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.